Efficacy of Kerecis Omega 3 in Comparison to Clinical Standard Procedures

Insel Gruppe AG, University Hospital Bern

Status: Withdrawn

Conditions: Leg Ulcer

Treatments: Device: Kerecis Omega 3; Procedure: Surgical debridement

Study type: Interventional

Funder types: Other

Identifiers

NCT06036485

Kerecis-1

Details and patient eligibility

About

Chronic leg ulcerations are a great burden for patients and the medical system alike. Frequent outpatient consultations with associated treatment costs and travel costs for the patient as well as psychosocial burdens remain an unmet problem in chronic wound care. There is an increasing need for definitive treatment of especially chronic venous and multifactorial chronic leg ulceration where arterial intervention is not a treatment option.

Minimal invasive surgical interventions that do not require skin grafting can be performed under local anesthesia in an outpatient setting even in multimorbid patients.

Kerecis Omega3 Wound is intact decellularized fish skin. The fish skin sheets contain fat, protein, elastin, glycans and other natural skin elements and it can be an effective treatment option in chronic leg ulcerations and is licensed for this use as a medical product in Switzerland. However, limited data without inter-wound bias is available for the use of Kerecis Omega 3 in chronic leg ulcerations.

In this study the investigators propose to investigate the efficacy of Kerecis Omega 3 according to objective wound surface measurements using standardized digital photographs in patients with chronic leg ulcerations. Efficacy will be evaluated against standard of care wound debridement.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any chronic leg ulcer > 4 weeks duration with delayed wound healing (reduction of wound surface of less than 40-50% within 4 weeks under adequate local therapy) without underlying treatable medical conditions
• Ulcer area at between 5cm2 and 60cm2
• Bacterial swab sampling prior to study
• Written study informed consent

Exclusion criteria

• History of Fish allergy or proven Fish allergy
• Pregnant or breast-feeding women
• Intention to become pregnant during the course of the study
• Wound not suitable for dressing: inflammation, fibrin coatings
• Inability to understand the study consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

Kerecis Omega 3

Experimental group

Treatment:

Device: Kerecis Omega 3

Surgical debridement

Active Comparator group

Treatment:

Procedure: Surgical debridement